Nicholas Kenyon

“Nitric oxide at the interface of therapeutics and biomarkers in asthma”

Asthma is one of the most common diseases in the world. New biomarkers and new therapies that can help in managing and treating this disease are sorely needed. Exhaled breath nitric oxide concentration is an increasingly used biomarker in asthma. We have been investigating whether drugs that potentially manipulate lung nitric oxide levels, either L-arginine or arginase inhibitors, could prove to be effective treatments for patients with asthma.

When:  Thurs. 4/26/12 4:10 PM

Where: 1005 GBSF